```json
{
"content": [
{
"type": "paragraph",
"content": "The Hay Fever Treatment market encompasses therapeutic solutions for allergic rhinitis, including antihistamines, nasal corticosteroids, and immunotherapy. With over 300 million people globally affected by hay fever, the industry is driven by rising allergy prevalence and innovation in treatment modalities."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Antihistamines", "Nasal Corticosteroids", "Immunotherapy"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44], // Antihistamines
[28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40], // Nasal Corticosteroids
[15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 32, 34] // Immunotherapy
]
}
},
{
"type": "paragraph",
"content": "The global Hay Fever Treatment market size reached $10.2 billion in 2025, with a projected CAGR of 5.8% from 2026 to 2033, reaching $15.6 billion by 2033. Key growth drivers include urbanization, climate change intensifying allergen exposure, and advancements in biologics for targeted therapies. North America remains the largest market due to high awareness and robust healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising urbanization and diagnostic accessibility. Regulatory support for novel therapies and digital health tools (e.g., telemedicine) are reshaping the landscape, alongside consumer demand for non-sedating and personalized treatment options."
}
]
}
```
